Bionovo, Inc. - Product Pipeline Review - Q4 2010

Bionovo, Inc. – Product Pipeline Review – Q4 2010

Summary

Global Market Direct’s pharmaceuticals report, “Bionovo, Inc. - Product Pipeline Review - Q4 2010” provides data on the company’s research and development focus. The report includes information on current developmental pipeline, complete with latest updates, and features on discontinued and dormant projects.

This report is built using data and information sourced from Global Markets Direct’s proprietary databases, Company’s corporate website, SEC filings, investor presentations and featured press releases, both from company and industry-specific third party sources, put together by Global Markets Direct’s team.

Scope

- Bionovo, Inc. - Brief company overview including business description, key information and facts, and its locations and subsidiaries.
- Review of current pipeline of Bionovo, Inc. human therapeutic division.
- Overview of pipeline therapeutics across various therapy areas.
- Coverage of current pipeline molecules in various stages of drug development, including the combination treatment modalities, across the globe.
- Product profiles for late stage and clinical stage products of Bionovo, Inc. with complete description of the product’s developmental history, mechanism of action, therapeutic class, target and major milestones.
- Recent updates of the Bionovo, Inc.’s pipeline in the last quarter.
- Key discontinued and dormant projects.
- Latest news and deals relating to the products.

Reasons to buy

- Evaluate Bionovo, Inc.’s strategic position with total access to detailed information on its product pipeline.
- Assess the growth potential of Bionovo, Inc. in its therapy areas of focus.
- Identify new drug targets and therapeutic classes in the Bionovo, Inc.’s R&D portfolio and develop key strategic initiatives to reinforce pipeline in those areas.
- Exploit in-licensing opportunities by identifying windows of opportunity to fill portfolio gaps.
- Exploit collaboration and partnership opportunities with Bionovo, Inc..
- Avoid Intellectual Property Rights related issues.
- Explore the dormant and discontinued projects of Bionovo, Inc. and identify potential opportunities in those areas.

List of Tables
List of Figures
Bionovo, Inc. Snapshot
Bionovo, Inc. Overview
Key Information
Key Facts
Bionovo, Inc. – Research and Development Overview
Key Therapeutic Areas
Bionovo, Inc. – Pipeline Review
Pipeline Products by Stage of Development
Pipeline Products – Monotherapy
Bionovo, Inc. – Pipeline Products Glance
Bionovo, Inc. – Late Stage Pipeline
Phase III Products/Combination Treatment Modalities
Bionovo, Inc. Clinical Stage Pipeline Products
Phase II Products/Combination Treatment Modalities
Bionovo, Inc.–Early Stage Pipeline Products
Pre-Clinical Products/Combination Treatment Modalities
Bionovo, Inc. – Drug Profiles
Menerba
Product Description
Mechanism of Action
R&D Progress
BN107
Product Description
Mechanism of Action
R&D Progress
BN108
Product Description
Mechanism of Action
R&D Progress
Bezielle
Product Description
Mechanism of Action
R&D Progress
Seala
Product Description
Mechanism of Action
R&D Progress
Bionovo, Inc. – Pipeline Analysis
Bionovo, Inc. – Pipeline Products by Therapeutic Class
Bionovo, Inc. Pipeline Products By Target
Bionovo, Inc. – Pipeline Products by Route of Administration
Bionovo, Inc. – Pipeline Products by Molecule Type
Bionovo, Inc. – Recent Pipeline Updates
Bionovo, Inc. – Company Statement
Bionovo, Inc. – Locations And Subsidiaries
Head Office
Recent Developments
Nov 10, 2010: Bionovo Receives FDA Approval For Clinical Development Plan Of Menerba
Sep 23, 2010: Bionovo Receives FDA Approval For Menerba Manufacturing Plan
Aug 30, 2010: Bionovo Receives Positive Guidance From FDA On Menerba
Aug 02, 2010: Bionovo Announces Publication Describing Menerba's Effect On Neural Pathways Related To Temperature Regulation
Jul 29, 2010: Bionovo To Advance Menerba to Phase III Clinical Testing In Europe
Apr 20, 2010: Bionovo Receives Patent For Bezielle For Treatment Of Metastatic Breast Cancer
Jan 14, 2010: Bionovo Announces Results From Phase 1B Clinical Trial Of Bezielle (BZL101) For Metastatic Breast Cancer
Dec 29, 2009: Bionovo Announces Publication Describing First Novel Dual mTOR Inhibitor, BN107, For The Treatment Of Breast Cancer
Oct 01, 2009: Bionovo Announces Publication Describing The Selective Anti-tumor Activity Of Its Drug Candidate BN108
Sep 03, 2009: Bionovo To Present Positive Results From Phase 2 Trial Of Menerba For Vasomotor Symptoms To The International Community
Financial Deals Landscape
Bionovo, Inc., Deals Volume Summary, 2004 to YTD 2010
Bionovo, Inc., Deals Summary By Region, 2004 to YTD 2010
Bionovo, Inc., Deals Summary, 2004 to YTD 2010
Bionovo, Inc. Detailed Deal Summary
Merger
Lighten Up Enterprises Merges With Bionovo
Equity Offering
Bionovo Completes Public Offering Of $19 Million
Bionovo Completes Public Offering Of $25.53 Million
Bionovo Completes Private Placement Of $15.78 Million
Bionovo Completes Private Placement Of $10.23 Million
Lighten Up Enterprises Completes Private Placement Of $2.13 Million
Bionovo Completes Private Placement Of $10 Million
Debt Offering
Bionovo Completes Public Offering Of Convertible Notes For $0.5 Million
Licensing Agreements
Bionovo Terminates Licensing Agreement With United Biotech
Appendix
Methodology
Coverage
Secondary Research
Primary Research
Expert Panel Validation
Contact Us
Disclaimer

Order Online - visit http://www.researchandmarkets.com/reports/1582661

Order by Fax - using the order form below

Order By Post - print the order form below and send to

Research and Markets,
Guinness Centre,
Taylors Lane,
Dublin 8,
Ireland.